GlassScriptPhysician profile
Sherri Nash
NPI 1861470759
$8,982.59
in general payments reported to CMS, 2019-2025
31 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what 93% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,681 · 2022: $1,682 · 2023: $2,522 · 2024: $1,551 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,537 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,536.55 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,304.97 | 2021-2025 | |
| Incyte Corporation | $1,286.26 | 2021-2025 | Opzelura, Opzelura, Iclusig |
| Sun Pharmaceutical Industries INC. | $801.41 | 2021-2025 | Ilumya, Blu-U, Winlevi |
| Leo Pharma INC. | $687.24 | 2022-2025 | Adbry |
| Janssen Biotech, INC. | $567.41 | 2021-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $446.56 | 2023-2025 | Dupixent |
| Ucb, INC. | $426.86 | 2021-2025 | Bimzelx, Cimzia |
| Surgenex LLC | $417.35 | 2025 | Ardeograft, Surgraft, Surmatrix |
| Pfizer INC. | $340.74 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $279.52 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $275.86 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $232.60 | 2021-2025 | Nemluvio |
| Lilly USA, LLC | $198.66 | 2021-2024 | Taltz, Olumiant, Zepbound |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $79.73 | 2021 | |
| Genzyme Corporation | $75.90 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $59.76 | 2021-2022 | |
| Revance Therapeutics, INC. | $54.93 | 2024 | Daxxify |
| Merz North America, INC. | $53.43 | 2021 | |
| Vyne Pharmaceuticals INC. | $52.89 | 2021 | |
| Amgen INC. | $49.53 | 2021-2024 | Otezla |
| Botanix Sb INC | $41.83 | 2025 | Sofdra |
| Biofrontera INC. | $39.93 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Fresenius Kabi USA, LLC | $30.80 | 2023 | Idacio |
| Avita Medical Americas, LLC | $27.07 | 2025 | Cohealyx, Recell, Permeaderm |
| Nabriva Therapeutics, Plc | $24.85 | 2022 | |
| Dermavant Sciences, INC. | $22.86 | 2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.84 | 2022 | |
| Almirall LLC | $22.23 | 2021 | |
| Organogenesis INC. | $22.23 | 2021 | |
| Arcutis Biotherapeutics, INC. | $18.74 | 2024 | Zoryve |
| Alfasigma USA, INC. | $17.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherri Nash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.